Biogen (BIIB) PT Lowered to $343 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Biogen (BIIB) PT Lowered to $290 at Oppenheimer on CRL for MDD
August 7, 2023 6:28 AM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $360.00) while maintaining a Outperform rating.
The analyst commented, "The MDD CRL for zuranolone deals BIIB a major blow but not a knockout. We expected BIIB to bolster topline growth... More
